{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-075241","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.158873+00:00","generated_at":"2026-06-13T16:16:38.392463+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rezolute to initiate Phase 3 for RZ358 in congenital HI outside US in Q4 2023; FDA restrictions prevent US inclusion","bullets":["Phase 3 sunRIZE study of RZ358 planned in Europe/ex-US starting Q4 2023; topline results expected 1H 2025.","FDA maintained age restriction (12+ years) and re-imposed dose cap based on rat toxicology; US inclusion currently infeasible.","Company evaluating nonclinical studies to address FDA concerns in parallel with ex-US Phase 3; cash $129M sustains ops through Q3 2025.","Phase 2b RIZE study showed RZ358 generally safe, well-tolerated, and effective in improving hypoglycemia.","Estimated congenital HI prevalence >10,000 in primary markets; >50% lack adequate treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-075241","json":"https://secwatch.observer/filing/0001104659-23-075241.json","markdown":"https://secwatch.observer/filing/0001104659-23-075241.md","text":"https://secwatch.observer/filing/0001104659-23-075241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/0001104659-23-075241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/tm2319715d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:16:38.392463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}